News · 26 weeks50+1000%
2026-03-012026-08-23
Mix2890d
- Insider14(50%)
- SEC Filings7(25%)
- Other4(14%)
- Earnings2(7%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form S-8 filed by Avita Medical Inc.S-8 - AVITA Medical, Inc. (0001762303) (Filer)
- INSIDERAmendment: CFO O'Toole David D bought $7,940 worth of shares (2,000 units at $3.97), increasing direct ownership by 1% to 152,927 units (SEC Form 4)4/A - AVITA Medical, Inc. (0001762303) (Issuer)
- PRAVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical OutcomesPrimary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18 VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, I
- SECAvita Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical to Host Investor Webinar BriefingVALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, at 9:00 a.m. Australian Eastern Standard Time). The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are invited to sub
- PRAVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceVALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026. AVITA Medical President and CEO Cary Vance will be speaking on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available under the Investor Relations Events & Presentations section of AVITA Medical’s website, at: https://ir.avitamedical.com/events-and-presentations Investors attending the conference may request a one-on-one me
- ANALYSTAvita Medical upgraded by BTIG Research with a new price targetBTIG Research upgraded Avita Medical from Neutral to Buy and set a new price target of $7.00
- SECAmendment: Avita Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K/A - AVITA Medical, Inc. (0001762303) (Filer)
- SECSEC Form 10-Q filed by Avita Medical Inc.10-Q - AVITA Medical, Inc. (0001762303) (Filer)
- SECAvita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow BreakevenVALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Q2 net revenue grew 18% year over year and 13% sequentially quarter-over-quarter to a record $21.7 million Revenue growth driven by continued execution across the Company's key commercial portfolio, led by RECELL® and supported by increasing adoption of Cohealyx® and PermeaDerm®, and complemented by consistent international revenueGross profit margin of 81.
- PRAVITA Medical to Announce Second Quarter 2026 Financial ResultsVALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical," or the "Company"), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 7, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. Second Quarter 2026 Webcast and Conference Call Information To listen to the conference call webcas
- PRAVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual MeetingFirst U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patientsFindings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells and improving operating room workflowRECELL GO is CE-marked in Europe and the U.K. and recently received regulatory authorization in Australia and New Zealand VALENCIA, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced the presentation of new clinical data highlighting the first documented
- INSIDERCFO O'Toole David D was granted 2,000 shares, increasing direct ownership by 1% to 152,927 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Woody Joseph Fralin bought $20,800 worth of shares (5,200 units at $4.00), increasing direct ownership by 5% to 107,961 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Woody Joseph Fralin bought $41,900 worth of shares (10,000 units at $4.19), increasing direct ownership by 11% to 102,761 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- SECSEC Form 424B5 filed by Avita Medical Inc.424B5 - AVITA Medical, Inc. (0001762303) (Filer)
- SECAvita Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- INSIDERDirector Woody Joseph Fralin bought $40,949 worth of shares (10,000 units at $4.09), increasing direct ownership by 12% to 92,761 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Tarnoff Michael E was granted 48,464 shares (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Cook Jeremy Curnock was granted 22,214 shares, increasing direct ownership by 56% to 62,050 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Crowe Suzanne was granted 22,214 shares, increasing direct ownership by 47% to 69,148 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Reed Jan Stern was granted 22,214 shares, increasing direct ownership by 44% to 73,225 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
RCEL FAQ
6 questionsWhat does Avita Medical Inc. do?
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells...Where does RCEL stock trade?
Avita Medical Inc. (RCEL) is listed on NASDAQ.What sector and industry is RCEL in?
Avita Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about RCEL?
Avita Medical Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $700.00 price target on 2026-08-07.What companies are similar to RCEL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare RCEL side-by-side with any of them on Quantisnow.How can I track RCEL on Quantisnow?
Quantisnow aggregates Avita Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RCEL to receive live email and push alerts on every new disclosure.